StayinFront, Inc., a leading global provider of customer relationship management systems and mobile sales force effectiveness tools, announced today that Chelsea Therapeutics has selected the StayinFront TouchRX mobile platform for their new sales force. Management will use StayinFront EdgeRx®, StayinFront’s SaaS-based CRM for Life Sciences and analytics solution, to monitor and manage field performance.
Chelsea Therapeutics, a biopharmaceutical development company, is deploying iPads across its newly formed field teams, including Medical Science Liaisons. With StayinFront TouchRx, which works online and offline and delivers valuable information to the point of sale, teams will capture, track and store key aspects of sales and marketing activity, including electronic signature capture and digital media presentations, quickly and easily. The ‘single point of accountability’ services model provided by StayinFront ensures the full value of the system. StayinFront EdgeRx delivers fully featured, SaaS-based CRM with integrated analytic capabilities. It includes everything an organization needs to optimize sales efforts and give management critical insight into performance right.
John Cones, National Sales Director for Chelsea Therapeutics, said,“The technology in StayinFront’s mobile CRM platform leverages the devices that engage healthcare professionals. Their demonstrated ability to rapidly deploy systems that maximize efficiencies in the field as well as deliver actionable insight to management was key in the decision to partner with them.”
Ken Arbadji, Vice President of Sales for StayinFront US, said,“With StayinFront TouchRx, Chelsea Therapeutics can expect maximum productivity and agility in the field as they commercialize their product line. Managers utilizing StayinFront EdgeRx will have faster decision making capabilities, which can further optimize their business growth and contribute to their success.”
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, NORTHERA™ (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).
StayinFront (stayinfront.com) is a global provider of the world’s most innovative customer relationship management solutions. From on-demand and on-premise CRM to mobile CRM access in the field using Androids™, iPhones and iPads, its ground-breaking software offers rich functionality, fast deployment and easy-to-use tools that increase sales force effectiveness. StayinFront has been selected as a strategic partner by many of the world’s top life sciences, consumer goods and business-to-business companies, improving efficiencies in over 65 countries and more than 25 languages. Headquartered in Fairfield, NJ, USA, StayinFront has offices in the United Kingdom, Ireland, India, Australia, Singapore and New Zealand.